These Stocks Can Make or Break Investors (Most Don't Understand How It Works)

Read the Full Report on Quantum BioPharma: https://www.marketbeat.com/y/yt1015/

Quantum BioPharma's Anthony Durkacz joins MarketBeat's Bridget Bennett to break down the FDA approval process and what investors need to know before buying biotech stocks. AI is speeding up drug discovery, but every drug still has to get through the same hoops, and most never make it.

In this interview, you'll hear what happens in phase 1, phase 2, and phase 3 clinical trials, why Anthony says most of the value tends to build after phase 2 data, when big pharma usually steps in, and how funding and dilution can make or break a small biotech company. He also shares an update on his company's phase 2 trial for multiple sclerosis, and he stresses that biotech carries a tremendous amount of risk.

FDA approval process, how to invest in biotech stocks, biotech stocks to buy now, clinical trial phases explained, phase 2 biotech stocks, AI biotech stocks, multiple sclerosis treatment, and what investors need to know about drug trials, all in this stock market update.

View Bridget's Buys here: https://www.marketbeat.com/bridget 📲 Text 'YouTube' to 68285 for FREE SMS breaking news alerts on top stocks.

Disseminated on behalf of Quantum BioPharma (NASDAQ:QNTM).

Read the full report: https://tomorrowinvestor.com/quantum-biopharma-new-breakthrough-treatment-for-multiple-sclerosis/

Learn more at the company website: https://www.quantumbiopharma.com/investors Disclosure/Disclaimer: We are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. This video was conducted on behalf of Quantum BioPharma and was funded by Think Ink Marketing. For our full disclaimer, please visit: https://tomorrowinvestor.com/quantum-biopharma-new-breakthrough-treatment-for-multiple-sclerosis/#disclaimer

For YouTube sponsorships, brand partnerships and advertising, send an email to: [email protected]

DISCLAIMER: MarketBeat's videos are for educational and informational purposes only and do not constitute financial, legal, or tax advice. We are not registered investment advisers, and nothing herein is a recommendation to buy, sell, or hold any security or strategy. Investing involves risk—including the potential loss of principal—so always perform your own due diligence and consult a licensed professional before acting. All opinions are those of the presenters and may change without notice. Presenters and MarketBeat personnel may own or trade the securities discussed. Past performance is not indicative of future results; any examples or case studies shown are illustrative and not typical. Some links or promotions mentioned may be affiliate partnerships that compensate MarketBeat at no additional cost to you. MarketBeat and its representatives accept no liability for any losses arising from reliance on this content.